ResearchResearch summary
Probiotic or fluconazole for vaginal yeast infection?
A small randomized trial compared oral Lactobacillus acidophilus LA-5 with fluconazole; its late culture result did not establish equivalence or recurrence prevention.
In this pathway
- Current topic
- Probiotic or fluconazole for vaginal yeast infection?Current

Sources behind these conclusions
Claim: A probiotic can replace established antifungal treatment and provide equivalent durable clinical cure for acute vulvovaginal candidiasis.
Not enough evidence · Unclear — All ten trials in the 2017 Cochrane review used probiotics as adjuncts rather than validated stand-alone replacements. A 2024 publication reports 96% versus 94% microbiological eradication after three days in 100 women assigned vaginal L. fermentum LF5 or miconazole, with recurrence among initially cleared participants of 5/48 versus 8/47 at two weeks (p=0.372). That single-blind, sponsor-funded trial was conducted in 1988-1992, has short follow-up, lacks a prespecified noninferiority framework adequate for equivalence, and has direct manufacturer-related conflicts. The triple-blind 2022-online/2023-issue trial randomized 80 women to 30 days of oral L. acidophilus LA-5 or one 150 mg fluconazole dose; at 60-65 days, negative cultures were observed in 7/36 (19.4%) versus 15/33 (45.5%) participants (Results/Table 2 p=0.021; the abstract reports p=0.016). The earlier visit had 10/36 versus 15/33 negative cultures (p=0.127). The late culture result is not a participant-level recurrence or defined clinical-cure outcome; attrition and denominator discrepancies remain, and the trial did not use an equivalence or noninferiority design. Together these strain-specific trials do not establish durable equivalence or a probiotic class effect. CDC states substantial evidence is absent and ISSVD concludes there is no demonstrated benefit; substituting an unvalidated product can delay effective treatment or evaluation of another cause.
Sources for this claim
- Efficacy of Limosilactobacillus fermentum in the management of vulvovaginal candidiasis: comparative analysis with topical miconazole in a single-blind randomized clinical trial (Randomized trial)
- Comparing the Effect of Probiotic and Fluconazole on Treatment and Recurrence of Vulvovaginal Candidiasis: a Triple-Blinded Randomized Controlled Trial (Randomized trial)
- Probiotics for vulvovaginal candidiasis in non-pregnant women (Systematic review)
- Sexually Transmitted Infections Treatment Guidelines, 2021: Vulvovaginal Candidiasis (Guideline)
- International Society for the Study of Vulvovaginal Disease Recommendations for the Diagnosis and Treatment of Vaginitis (Guideline)
Bottom line
This small trial did not establish that oral Lactobacillus acidophilus LA-5 can replace fluconazole. At 60–65 days, negative cultures were less frequent after LA-5, but one culture check is not a defined clinical cure or symptomatic recurrence outcome.
Why this source matters
Unlike probiotic add-on studies, this trial directly compared a probiotic used by itself with an antifungal. Its result helps test a replacement claim, while its limits prevent a conclusion about equivalence or other products.
Study and population
The triple-blind randomized trial enrolled 80 married women with culture-confirmed acute vulvovaginal candidiasis in Tabriz, Iran. The abstract gives an age range of 18–49, while the Methods give 15–49. The trial excluded recurrent VVC, pregnancy, lactation, menopause, diabetes and other chronic disease, and several other groups.
What was tested
Forty participants received one oral capsule daily for 30 days containing L. acidophilus LA-5, stated as 1 × 10⁹ CFU/g; the total CFU per capsule was not reported. Forty received a single 150 mg oral fluconazole dose. Each group also received matching placebos; the trial did not add the probiotic to fluconazole.
Results
At the first follow-up, negative cultures were found in 10/36 (27.8%) participants in the probiotic group and 15/33 (45.5%) in the fluconazole group (p=0.127). At 60–65 days, the counts were 7/36 (19.4%) and 15/33 (45.5%) (Results/Table 2 p=0.021; abstract p=0.016). More fluconazole-group participants reported no itching at the second follow-up: 27/33 versus 20/36 (81.8% versus 55.6%, p=0.019). The article's side-effect paragraph reports two cases in each group, but its flow chart lists three probiotic and six fluconazole losses related to side effects.
Applicability
These results concern one oral LA-5 product, one 30-day schedule, and women with an acute culture-confirmed episode in one Iranian city. The trial excluded recurrent VVC and did not test probiotics taken alongside antifungal treatment. Its later culture check does not establish recurrence prevention or equivalence in clinical cure.
Limitations
The paper gives inconsistent follow-up windows and p-values, and several outcome-table denominators do not reconcile. Although the authors describe intention-to-treat analysis, the culture results use smaller observed follow-up groups and no missing-data method is described. The study names no primary outcome or power calculation and was not designed to establish equivalence. It also does not show which participants changed from a negative culture to a positive one, so the later culture result is not a relapse rate.
Contribution to the evidence
Contradictory for the replacement claim: late observed culture negativity favored fluconazole over LA-5. This result is strain-specific and limited by missing follow-up, outcome-definition, and reporting problems; it does not establish a class effect or a clinical recurrence outcome.
Practical change
No practical change. The trial does not show that probiotic monotherapy is equivalent to established antifungal treatment or prevents recurrent VVC. Do not use it as a basis for replacing antifungal treatment.
Funding and conflicts
Tabriz University of Medical Sciences funded the study and reported no role in its design or conduct, writing, or submission. The authors declared no competing interests.
Source
Read the original publication (published online 5 October 2022; journal issue October 2023).
Study type, population, and sample scale
- Study type
- Triple-blind randomized controlled trial
- Population
- Married women with culture-confirmed acute vulvovaginal candidiasis at hospitals and health centers in Tabriz, Iran; recurrent VVC and several higher-risk or chronic conditions were excluded
- Sample scale
- 80 women randomized, 40 per group; culture outcomes at follow-up were reported for 36 probiotic and 33 fluconazole participants
Results
- At the first follow-up, described as 35–40 days in Results but 30–35 days in Methods, negative cultures were reported in 10/36 (27.8%) probiotic participants and 15/33 (45.5%) fluconazole participants (p=0.127).
- At 60–65 days, negative cultures were reported in 7/36 (19.4%) probiotic participants and 15/33 (45.5%) fluconazole participants (Results/Table 2 p=0.021; the abstract reports p=0.016). The article does not report participant-level transitions that would identify recurrence among people who first cleared culture.
- At the second follow-up, no itching was reported for 20/36 (55.6%) probiotic participants and 27/33 (81.8%) fluconazole participants (p=0.019). The paper reports two side-effect cases in each group, while its flow chart lists 3 and 6 side-effect-related losses to follow-up.
Limitations
- The study calls the later assessment recurrence, but measured culture status at one visit 60–65 days after treatment began.
- It did not define a symptomatic recurrence event or report participant-level movement from an earlier negative culture; recurrent VVC was excluded.
- The article describes analyses as intention-to-treat but reports culture follow-up for 36 of 40 probiotic participants and 33 of 40 fluconazole participants.
- Attrition, side-effect-related losses, and denominators differ across some outcome tables; missing-data handling and imputation are not reported.
- Follow-up timing and statistical reporting are inconsistent.
- Methods and Results give different first-visit windows, the abstract and Results/Table 2 differ on the late culture p-value, and some symptom-table denominators do not reconcile.
- The paper does not identify a primary outcome or describe a sample-size calculation or equivalence/noninferiority design.
- Culture negativity at one visit cannot establish durable clinical equivalence; the small single-center sample and population exclusions limit generalizability.
Applies to
- The exact comparison of 30 days of oral L. acidophilus LA-5 with a single 150 mg oral fluconazole dose in this small acute-VVC trial
Does not apply to
- Probiotic supplements as a class, other strains or doses, adjunct probiotic use, confirmed recurrent VVC, or durable symptomatic recurrence prevention
Contribution to the current conclusion
Contradictory
This is a direct comparison of one oral probiotic strain used alone with single-dose fluconazole. At 60–65 days, observed culture negativity favored fluconazole, but the trial did not define clinical cure or recurrence, test equivalence, or establish a probiotic class effect; its reporting and follow-up limitations preserve the current no-substitution conclusion.
Related evidence mapPractical change or no change
No practical change. The observed late culture result favored fluconazole, but this small strain-specific study did not establish equivalence, clinical recurrence, or a reason to replace established antifungal treatment.
Funding and conflicts
- Funding
- Tabriz University of Medical Sciences funded the study and reported no role in its design or conduct, manuscript writing, or submission.
- Conflicts
- The authors declared no competing interests.
- Paper date
- 2022-10-05
Sources
View all 1 source
- Comparing the Effect of Probiotic and Fluconazole on Treatment and Recurrence of Vulvovaginal Candidiasis: a Triple-Blinded Randomized Controlled Trial
- Source type
- Randomized trial
- Published
- 2022-10-05